ArticleIndian dermatology online journal

A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India.

Kabir Sardana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.